Abstract

1 YC-1, an activator of soluble guanylate cyclase (sGC), has been shown to increase the intracellular cGMP concentration. This study was designed to investigate the signaling pathway involved in the YC-1-induced COX-2 expression in A549 cells. 2 YC-1 caused a concentration- and time-dependent increase in COX activity and COX-2 expression in A549 cells. Pretreatment of the cells with the sGC inhibitor (ODQ), the protein kinase G (PKG) inhibitor (KT-5823), and the PKC inhibitors (Go 6976 and GF10923X), attenuated the YC-1-induced increase in COX activity and COX-2 expression. 3 Exposure of A549 cells to YC-1 caused an increase in PKC activity; this effect was inhibited by ODQ, KT-5823 or Go 6976. Western blot analyses showed that PKC-α, -ι, -λ, -ζ and -μ isoforms were detected in A549 cells. Treatment of A549 cells with YC-1 or PMA caused a translocation of PKC-α, but not other isoforms, from the cytosol to the membrane fraction. Long-term (24 h) treatment of A549 cells with PMA down-regulated the PKC-α. 4 The MEK inhibitor, PD 98059 (10-50 μM), concentration-dependently attenuated the YC-1-induced increases in COX activity and COX-2 expression. Treatment of A549 cells with YC-1 caused an activation of p44/42 MAPK; this effect was inhibited by KT-5823, Go 6976, long-term (24 h) PMA treatment or PD98059, but not the p38 MAPK inhibitor, SB 203580. 5 These results indicate that in human pulmonary epithelial cells, YC-1 might activate PKG through an upstream sGC/cGMP pathway to elicit PKC-α activation, which in turn, initiates p44/42 MAPK activation, and finally induces COX-2 expression.

Original languageEnglish
Pages (from-to)558-567
Number of pages10
JournalBritish Journal of Pharmacology
Volume136
Issue number4
Publication statusPublished - 2002

Fingerprint

Cyclic GMP-Dependent Protein Kinases
Prostaglandin-Endoperoxide Synthases
Mitogen-Activated Protein Kinases
Mitogen-Activated Protein Kinase 3
Protein Isoforms
Mitogen-Activated Protein Kinase Kinases
p38 Mitogen-Activated Protein Kinases
Protein Kinase Inhibitors
A549 Cells
Cytosol
Western Blotting
Epithelial Cells
Lung
Membranes

Keywords

  • A549 cells
  • Cyclo-oxygenase-2
  • Guanylate cyclase
  • P44/42 MAPK
  • Protein kinase C
  • YC-1

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{027e9552caa54847aafa9faf3d193eb5,
title = "YC-1 increases cyclo-oxygenase-2 expression through protein kinase G- and p44/42 mitogen-activated protein kinase-dependent pathways in A549 cells",
abstract = "1 YC-1, an activator of soluble guanylate cyclase (sGC), has been shown to increase the intracellular cGMP concentration. This study was designed to investigate the signaling pathway involved in the YC-1-induced COX-2 expression in A549 cells. 2 YC-1 caused a concentration- and time-dependent increase in COX activity and COX-2 expression in A549 cells. Pretreatment of the cells with the sGC inhibitor (ODQ), the protein kinase G (PKG) inhibitor (KT-5823), and the PKC inhibitors (Go 6976 and GF10923X), attenuated the YC-1-induced increase in COX activity and COX-2 expression. 3 Exposure of A549 cells to YC-1 caused an increase in PKC activity; this effect was inhibited by ODQ, KT-5823 or Go 6976. Western blot analyses showed that PKC-α, -ι, -λ, -ζ and -μ isoforms were detected in A549 cells. Treatment of A549 cells with YC-1 or PMA caused a translocation of PKC-α, but not other isoforms, from the cytosol to the membrane fraction. Long-term (24 h) treatment of A549 cells with PMA down-regulated the PKC-α. 4 The MEK inhibitor, PD 98059 (10-50 μM), concentration-dependently attenuated the YC-1-induced increases in COX activity and COX-2 expression. Treatment of A549 cells with YC-1 caused an activation of p44/42 MAPK; this effect was inhibited by KT-5823, Go 6976, long-term (24 h) PMA treatment or PD98059, but not the p38 MAPK inhibitor, SB 203580. 5 These results indicate that in human pulmonary epithelial cells, YC-1 might activate PKG through an upstream sGC/cGMP pathway to elicit PKC-α activation, which in turn, initiates p44/42 MAPK activation, and finally induces COX-2 expression.",
keywords = "A549 cells, Cyclo-oxygenase-2, Guanylate cyclase, P44/42 MAPK, Protein kinase C, YC-1",
author = "Chang, {Ming Shyan} and Lee, {Wen Sen} and Teng, {Che Ming} and Lee, {Horng Mo} and Sheu, {Joen Rong} and George Hsiao and Chien-Huang Lin",
year = "2002",
language = "English",
volume = "136",
pages = "558--567",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - YC-1 increases cyclo-oxygenase-2 expression through protein kinase G- and p44/42 mitogen-activated protein kinase-dependent pathways in A549 cells

AU - Chang, Ming Shyan

AU - Lee, Wen Sen

AU - Teng, Che Ming

AU - Lee, Horng Mo

AU - Sheu, Joen Rong

AU - Hsiao, George

AU - Lin, Chien-Huang

PY - 2002

Y1 - 2002

N2 - 1 YC-1, an activator of soluble guanylate cyclase (sGC), has been shown to increase the intracellular cGMP concentration. This study was designed to investigate the signaling pathway involved in the YC-1-induced COX-2 expression in A549 cells. 2 YC-1 caused a concentration- and time-dependent increase in COX activity and COX-2 expression in A549 cells. Pretreatment of the cells with the sGC inhibitor (ODQ), the protein kinase G (PKG) inhibitor (KT-5823), and the PKC inhibitors (Go 6976 and GF10923X), attenuated the YC-1-induced increase in COX activity and COX-2 expression. 3 Exposure of A549 cells to YC-1 caused an increase in PKC activity; this effect was inhibited by ODQ, KT-5823 or Go 6976. Western blot analyses showed that PKC-α, -ι, -λ, -ζ and -μ isoforms were detected in A549 cells. Treatment of A549 cells with YC-1 or PMA caused a translocation of PKC-α, but not other isoforms, from the cytosol to the membrane fraction. Long-term (24 h) treatment of A549 cells with PMA down-regulated the PKC-α. 4 The MEK inhibitor, PD 98059 (10-50 μM), concentration-dependently attenuated the YC-1-induced increases in COX activity and COX-2 expression. Treatment of A549 cells with YC-1 caused an activation of p44/42 MAPK; this effect was inhibited by KT-5823, Go 6976, long-term (24 h) PMA treatment or PD98059, but not the p38 MAPK inhibitor, SB 203580. 5 These results indicate that in human pulmonary epithelial cells, YC-1 might activate PKG through an upstream sGC/cGMP pathway to elicit PKC-α activation, which in turn, initiates p44/42 MAPK activation, and finally induces COX-2 expression.

AB - 1 YC-1, an activator of soluble guanylate cyclase (sGC), has been shown to increase the intracellular cGMP concentration. This study was designed to investigate the signaling pathway involved in the YC-1-induced COX-2 expression in A549 cells. 2 YC-1 caused a concentration- and time-dependent increase in COX activity and COX-2 expression in A549 cells. Pretreatment of the cells with the sGC inhibitor (ODQ), the protein kinase G (PKG) inhibitor (KT-5823), and the PKC inhibitors (Go 6976 and GF10923X), attenuated the YC-1-induced increase in COX activity and COX-2 expression. 3 Exposure of A549 cells to YC-1 caused an increase in PKC activity; this effect was inhibited by ODQ, KT-5823 or Go 6976. Western blot analyses showed that PKC-α, -ι, -λ, -ζ and -μ isoforms were detected in A549 cells. Treatment of A549 cells with YC-1 or PMA caused a translocation of PKC-α, but not other isoforms, from the cytosol to the membrane fraction. Long-term (24 h) treatment of A549 cells with PMA down-regulated the PKC-α. 4 The MEK inhibitor, PD 98059 (10-50 μM), concentration-dependently attenuated the YC-1-induced increases in COX activity and COX-2 expression. Treatment of A549 cells with YC-1 caused an activation of p44/42 MAPK; this effect was inhibited by KT-5823, Go 6976, long-term (24 h) PMA treatment or PD98059, but not the p38 MAPK inhibitor, SB 203580. 5 These results indicate that in human pulmonary epithelial cells, YC-1 might activate PKG through an upstream sGC/cGMP pathway to elicit PKC-α activation, which in turn, initiates p44/42 MAPK activation, and finally induces COX-2 expression.

KW - A549 cells

KW - Cyclo-oxygenase-2

KW - Guanylate cyclase

KW - P44/42 MAPK

KW - Protein kinase C

KW - YC-1

UR - http://www.scopus.com/inward/record.url?scp=0035984941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035984941&partnerID=8YFLogxK

M3 - Article

C2 - 12055134

AN - SCOPUS:0035984941

VL - 136

SP - 558

EP - 567

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 4

ER -